Journal Browser

Journal Browser

Molecular Basic Research in Cardiology

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 458

Special Issue Editor

Special Issue Information

Dear Colleagues,

“Molecular Basic Research in Cardiology” is a Special Issue focusing on basic molecular research in cardiology. We aim to gain insights into the molecular mechanisms of heart disease in order to promote the prevention and treatment of heart disease. The hot topics in this field include cardiac cell biology, cardiac development and regeneration, cardiac metabolism, cardiac electrophysiology, cardiac pathophysiology, cardiac immunology, and cardiac genomics.

Potential research topics for this Special Issue include the function and regulation mechanism of cardiac cells, the molecular mechanism of cardiac development and regeneration, the relationship between cardiac metabolism and energy balance, the molecular basis of cardiac electrophysiology and arrhythmia, the molecular mechanism of cardiac pathophysiology and cardiac disease, the molecular regulation of cardiac immunology and cardiac inflammation, and the relationship between cardiac genomics and genetic variation and heart disease.

Dr. Francesco Nappi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cardiac cell biology
  • cardiac development and regeneration
  • cardiac metabolism
  • cardiac electrophysiology
  • cardiac pathophysiology
  • cardiac immunology
  • cardiac genomics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


23 pages, 4078 KiB  
P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application
by Francesco Nappi
Int. J. Mol. Sci. 2024, 25(14), 7575; https://doi.org/10.3390/ijms25147575 - 10 Jul 2024
Viewed by 300
Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent this, antiplatelet agents are [...] Read more.
Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent this, antiplatelet agents are used in clinical settings to limit platelet activation in patients at risk of arterial thrombotic events. However, their use can be associated with a significant risk of bleeding. An enhanced comprehension of platelet signaling mechanisms should facilitate the identification of safer targets for antiplatelet therapy. Over the past decade, our comprehension of the breadth and intricacy of signaling pathways that orchestrate platelet activation has expanded exponentially. Several recent studies have provided further insight into the regulation of platelet signaling events and identified novel targets against which to develop novel antiplatelet agents. Antiplatelet drugs are essential in managing atherothrombotic vascular disease. The current antiplatelet therapy in clinical practice is limited in terms of safety and efficacy. Novel compounds have been developed in response to patient variability and resistance to aspirin and/or clopidogrel. Recent studies based on randomized controlled trials and systematic reviews have definitively demonstrated the role of antiplatelet therapy in reducing the risk of cardiovascular events. Antiplatelet therapy is the recommended course of action for patients with established atherosclerosis. These studies compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. However, in patients undergoing percutaneous coronary intervention, it is still unclear whether the efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy depends on the type of P2Y12 inhibitor. This paper focuses on the advanced-stage evaluation of several promising antiplatelet drugs. Full article
(This article belongs to the Special Issue Molecular Basic Research in Cardiology)
Show Figures

Figure 1

Back to TopTop